Which of the following statements is true of participation in the context of building support for change?
A. Employees need to participate in a change after it occurs, not before.
B. Participation merely encourages compliance with change.
C. When employees participate in change from the beginning, they feel demotivated and feel their ideas will be rejected.
D. As participation increases, resistance to change tends to decrease.
Answer: D
You might also like to view...
For many technology and pharmaceutical firms:
a. a large portion of their value to an acquirer might relate to in-process research and development (IPR&D). b. in-process research and development (IPR&D) acquired in a business combination that meets the separability criterion as an asset is recognized and measured initially at fair value. c. The firm that developed the in-process research and development (IPR&D) expensed the costs as they were incurred. d. all of the above e. none of the above
Give examples of the kinds of information flows that take place between a store and its consumers, a distribution center, and a manufacturer.
What will be an ideal response?
Which of the following is true regarding FDA approval of drug labels in relation to state law claims for failure to warn?
a. FDA approval of the label on a brand-name prescription drug does not preempt state failure-to-warn claims arising out of injuries caused by the drug nor does FDA approval of the label preempt state failure-to-warn claims related to approved generic drugs bearing the FDA-mandated label. b. FDA approval of the label on a brand-name prescription drug preempts state failure-to-warn claims arising out of injuries caused by the drug, and federal law also preempts state failure-to-warn claims related to approved generic drugs as long as they bear the FDA-mandated label. c. FDA approval of the label on a brand-name prescription drug preempts state failure-to-warn claims arising out of injuries caused by the drug, but federal law does not preempt state failure-to-warn claims related to approved generic drugs bearing the FDA-mandated label. d. FDA approval of the label on a brand-name prescription drug does not preempt state failure-to-warn claims arising out of injuries caused by the drug, but federal law preempts state failure-to-warn claims related to approved generic drugs as long as they bear the FDA-mandated label.
Describe the relation between group norms, group cohesiveness, and performance?
What will be an ideal response?